InflaRx Reports Third Quarter 2023 Financial Results and Pro

Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) ...

Related Keywords

Germany , United States , Munich , Bayern , German , Thomas Taapken , Nielsc Riedemann , Regina Lutz , Laurie Doyle , Katja Arnold , Inflarx Stops Development Of Vilobelimab , Inflarx Pharmaceuticals Inc , Development Expenses , European Union , German Ministry Of Education , Mc Services , European Medicines Agency , Nasdaq , Development Of Vilobelimab , Exchange Commission , Drug Administration , German Ministry Of Health , Chief Executive Officer , Positive Topline Results , Single Ascending Dose , Phasei Trial Support Best In Class Potential , Pyoderma Gangrenosum , Authorization Application , Critically Ill , European Committee , Medicinal Products , Human Use , Emergency Use Authorization , Cutaneous Squamous Cell Carcinoma , German Ministry , Chief Financial Officer , Marketing Expenses , Administrative Expenses , Financial Result , Cash Used , Operating Activities , Capital Resources , Financial Information , Annual Report , Condensed Consolidated Statements , Comprehensive Loss , Comprehensive Income , Financial Position , Shareholder Equity , Cash Flows , Inflarx Pharmaceuticals , Ann Arbor , German Federal Government ,